Sanford C. Bernstein Cuts BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target to $82.00

BioMarin Pharmaceutical (NASDAQ:BMRN) had its price target cut by investment analysts at Sanford C. Bernstein from $94.00 to $82.00 in a research report issued on Tuesday,Benzinga reports. The firm currently has an “outperform” rating on the biotechnology company’s stock. Sanford C. Bernstein’s price target would suggest a potential upside of 53.08% from the stock’s current price.

A number of other analysts have also weighed in on the stock. Oppenheimer reduced their price objective on shares of BioMarin Pharmaceutical from $98.00 to $95.00 and set an “outperform” rating on the stock in a research report on Tuesday, February 24th. Royal Bank Of Canada reissued a “sector perform” rating and issued a $66.00 price objective on shares of BioMarin Pharmaceutical in a research report on Tuesday. Bank of America reduced their price objective on shares of BioMarin Pharmaceutical from $97.00 to $85.00 and set a “buy” rating on the stock in a research report on Wednesday, March 11th. Barclays increased their price objective on shares of BioMarin Pharmaceutical from $80.00 to $105.00 and gave the stock an “overweight” rating in a research report on Tuesday, March 3rd. Finally, Wolfe Research reissued an “outperform” rating on shares of BioMarin Pharmaceutical in a research report on Monday, March 16th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat, BioMarin Pharmaceutical has an average rating of “Moderate Buy” and a consensus target price of $90.32.

BioMarin Pharmaceutical Price Performance

Shares of NASDAQ BMRN traded down $1.89 during mid-day trading on Tuesday, hitting $53.57. 1,582,539 shares of the company’s stock traded hands, compared to its average volume of 2,007,297. The company’s 50-day moving average is $56.93 and its two-hundred day moving average is $56.32. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.21 and a quick ratio of 3.50. The company has a market capitalization of $10.35 billion, a P/E ratio of 30.16, a PEG ratio of 0.54 and a beta of 0.23. BioMarin Pharmaceutical has a 1 year low of $50.76 and a 1 year high of $66.28.

Insider Transactions at BioMarin Pharmaceutical

In other BioMarin Pharmaceutical news, EVP Charles Greg Guyer sold 16,486 shares of the stock in a transaction dated Wednesday, March 11th. The shares were sold at an average price of $60.46, for a total transaction of $996,743.56. Following the transaction, the executive vice president directly owned 79,953 shares in the company, valued at $4,833,958.38. This represents a 17.09% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Gregory R. Friberg sold 6,326 shares of BioMarin Pharmaceutical stock in a transaction that occurred on Thursday, February 26th. The shares were sold at an average price of $60.38, for a total transaction of $381,963.88. Following the transaction, the executive vice president directly owned 37,578 shares in the company, valued at approximately $2,268,959.64. The trade was a 14.41% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.85% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On BioMarin Pharmaceutical

Several institutional investors have recently bought and sold shares of the business. CIBC Private Wealth Group LLC increased its holdings in BioMarin Pharmaceutical by 38.2% during the fourth quarter. CIBC Private Wealth Group LLC now owns 648 shares of the biotechnology company’s stock valued at $39,000 after buying an additional 179 shares during the period. Northwestern Mutual Investment Management Company LLC boosted its stake in BioMarin Pharmaceutical by 0.4% in the fourth quarter. Northwestern Mutual Investment Management Company LLC now owns 42,982 shares of the biotechnology company’s stock valued at $2,554,000 after acquiring an additional 183 shares in the last quarter. Nisa Investment Advisors LLC boosted its stake in BioMarin Pharmaceutical by 7.7% in the fourth quarter. Nisa Investment Advisors LLC now owns 2,741 shares of the biotechnology company’s stock valued at $163,000 after acquiring an additional 195 shares in the last quarter. Grandfield & Dodd LLC boosted its stake in BioMarin Pharmaceutical by 1.2% in the third quarter. Grandfield & Dodd LLC now owns 18,967 shares of the biotechnology company’s stock valued at $1,027,000 after acquiring an additional 217 shares in the last quarter. Finally, EverSource Wealth Advisors LLC boosted its stake in BioMarin Pharmaceutical by 3.4% in the third quarter. EverSource Wealth Advisors LLC now owns 7,151 shares of the biotechnology company’s stock valued at $387,000 after acquiring an additional 235 shares in the last quarter. 98.71% of the stock is owned by hedge funds and other institutional investors.

More BioMarin Pharmaceutical News

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: Q1 revenue beat estimates and company raised full?year revenue guidance to $3.825B–$3.925B, citing portfolio additions (GALAFOLD®, POMBILITI® + OPFOLDA®) as growth drivers — this supports longer?term top?line growth expectations. PR Newswire: BioMarin Reports First Quarter 2026 Financial and Operating Results
• Positive Sentiment: Royal Bank of Canada reaffirmed its “sector perform” rating and set a $66 price target (~21% upside from current levels), which could provide analyst?driven support if sentiment improves. TickerReport / Benzinga: RBC reaffirms rating, $66 PT
• Neutral Sentiment: HC Wainwright reaffirmed a “neutral” rating with a $55 price target — little change to sell?side consensus and a reminder of mixed analyst views. TickerReport / Benzinga: HC Wainwright reaffirmation
• Neutral Sentiment: Full Q1 earnings call transcript and slide deck are available for details on drivers and margin outlook; these materials may clarify management’s path to margin improvement. Seeking Alpha: Q1 2026 earnings call transcript
• Negative Sentiment: Q1 EPS of $0.76 missed the Zacks consensus of $0.94 and fell year?over?year, a clear near?term earnings disappointment that weighs on valuation multiples. Zacks: Q1 earnings lag estimates
• Negative Sentiment: FY EPS guidance was set at $4.85–$5.05 vs. a Street consensus near $4.98 — a mild shortfall that, combined with the EPS miss, increases near?term investor caution despite revenue upside. BioMarin Q1 press materials (slide deck / press release)

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.